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Cardiovascular diseases are growing burden in westernized
countries.Cardiovasculardiseases,includingatherosclerosis,
associate with chronic inflammation. The goal of this special
issue is to highlight the inflammatory nature of cardiovas-
cular diseases and their association with the production of
cytokines, reactive oxygen species (ROS), and SUMOylation
inatheroscleroticplaques.Inaddition,biomarkersthatreflect
the biological processes of progression and destabilization of
atherosclerotic plaques would provide noninvasive means to
identify high-risk patients for cardiovascular events. Armed
with this understanding, it is hoped that novel therapeutic
strategies will aid in the prevention and management of
chroniccardiovascularinflammationandbenefitthepatients
afflicted with cardiovascular disease.
Increasing pieces of evidence support the important
role of ROS and cytokine production in the process of
atherosclerosis via regulating various signaling pathways
leading to vascular inflammation. In the present review, N.
T.Leetal.focusedonROS-mediatedSUMOylation,whichis
one of the posttranslational modifications, and discussed its
possible implications on vascular inflammation. It becomes
apparent that ROS production can regulate the process of
SUMOylation in both vasculature and heart and mediate a
numberofbiologicalprocesses,suchasapoptosisandinflam-
mation. The crucial role especially of ERK5, p53, and MK2
SUMOylationin theprocess ofendothelialinflammationhas
beendiscussed.Furthermore,arecentstudyfromtheirgroup
has found a strong correlation between C247TS N Po ft h e
NADPH oxidase p22phox subunit and cardiovascular events
in postinfarction patients with concurrently high levels of
HDL cholesterol and CRP. These data suggest that ROS not
only affects the intracellular signaling but also can produce
dysfunctional HDL. Since ROS can increase nitration and
chlorinationofspecifictyrosineresiduesonapolipoproteinA-
I, which is a major apolipoprotein component of HDL
p a r t i c l e sa n dm a j o rm e d i a t o ro fH D Lf u n c t i o n a l i t i e s ,i ti s
intriguing to assume that C247TS N Po ft h eN A D P Ho x i d a s e
p22phox subunit relates to this HDL modification, leading to
dysfunctional HDL.
R .N .E n g l a n da n dM .V .A u t i e r id i s c u s s e dt h er o l eo f
novel and undercharacterized cytokine IL-19 on vascular
inflammation. IL-19 shows pleotropic effects on vascular
wall. It can inhibit proliferative and proinflammatory gene
expression in vascular smooth muscle cells (VSMCs) via NF-
kB independent signaling, which is very different from the
effectsofIL-10.Thepossibleinvolvementoftheexpressionof
suppressorofcytokinesignaling5(SOCS5),humanRantigen
(HuR), and hem oxygenase-1 (HO-1) in this inhibitory effect
hasbeendiscussed.IncontrasttoVSMCs,IL-19showedpro-
liferative,promigratory,andproangiogeniceffectsinvascular
endothelial cells (ECs), although its role in EC inflammation
remains unclear. Since IL-19 can inhibit ROS production and
atherosclerosisformationinamousemodel,investigationthe
exactmechanismsofandinterplaybetweenIL-19andROSin
both VSMCs and ECs will be valuable for orchestrating anti-
inflammatory therapies for cardiovascular events.
Biomarkers can reflect the biological processes of disease
progression. For instance, CRP levels have been shown to2 International Journal of Inflammation
be predictive of cardiovascular risk. However, CRP is a non-
specific inflammatory marker that is affected by any inflam-
matory conditions. Therefore, it is important to develop
biomarkers that specifically report the biological processes in
atherosclerosis and other cardiovascular diseases, associated
with chronic inflammation. N. Kafkas et al. showed that
serum neutrophil gelatinase-associated lipocalin (NGAL)
levelswereincreasedinpatientswithcoronaryarterydisease.
They propose that NGAL could be used to discriminate
patients with acute coronary syndrome from those who are
with stable angina or without coronary artery diseases. V.
Panichi et al. review newer biomarkers, including CD40
ligand and pentraxin-3 that reflect chronic inflammation in
cardiovascular and renal diseases. D. Vasic and D. Walcher
summarize the current knowledge about C-peptide as a
biomarker and bioactive molecule. The deposition of C-
peptide may promote inflammation.
The docking proteins of the Grb2-associated binder
family (Gab1, Gab2, and Gab3) serve as important signal-
ing compartments. They may amplify and integrate signal
transduction pathways in response to various stimuli such
as cytokines. Interestingly, recent evidence has linked abnor-
mal Gab signaling with human diseases including cancer
and cardiovascular disease, for which inflammation plays a
key role. Y. Nakaoka and I. Komuro. extensively described
molecular structure, recruitment, and phosphorylation of
Gab proteins and discussed their role in cardiovascular and
cancer inflammation.
Anemergingconceptsuggeststhatchronicinflammation
participates in the pathogenesis of atherosclerosis and other
cardiovascular diseases. Thus, controlling proinflammatory
pathwayssuchasROS-mediatedSUMOylationmayattenuate
such diseases. The goal of this thematic series is to highlight
emerging proinflammatory mechanisms involved in cardio-
vascular inflammation. We believe that this issue will offer
updated concepts and help readers develop ideas leading to
future investigations and new drug development.
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